Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).

(2017) K. Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study

(2012) I.-M. Chen et al.   BLOOD

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

(2012) Oliver Weigert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

(2011) E Normant et al.   ONCOGENE

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program

(2011) Min H. Kang et al.   PEDIATRIC BLOOD & CANCER

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

(2010) R. C. Harvey et al.   BLOOD

HIF-1α and STAT3 client proteins interacting with the cancer chaperone Hsp90: Therapeutic considerations

(2010) Hanna Leah Kim et al.   CANCER BIOLOGY & THERAPY

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

(2010) T. Sasaki et al.   CANCER RESEARCH

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

(2010) S. De Brouwer et al.   CLINICAL CANCER RESEARCH

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program

(2010) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia

(2009) Charles G Mullighan et al.   NATURE GENETICS

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

(2008) D. B. Solit et al.   CLINICAL CANCER RESEARCH

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program

(2008) Malcolm A. Smith et al.   PEDIATRIC BLOOD & CANCER

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER